These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185 [TBL] [Abstract][Full Text] [Related]
11. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775 [TBL] [Abstract][Full Text] [Related]
12. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543 [TBL] [Abstract][Full Text] [Related]
13. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells. Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961 [TBL] [Abstract][Full Text] [Related]
15. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma. Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab in the Treatment of Hodgkin Lymphoma. Ansell SM Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581 [TBL] [Abstract][Full Text] [Related]
17. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Jalali S; Price-Troska T; Bothun C; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Dong H; Ansell SM Blood Cancer J; 2019 Feb; 9(3):22. PubMed ID: 30783096 [TBL] [Abstract][Full Text] [Related]
18. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145 [TBL] [Abstract][Full Text] [Related]
19. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma. Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000 [TBL] [Abstract][Full Text] [Related]
20. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Green MR; Rodig S; Juszczynski P; Ouyang J; Sinha P; O'Donnell E; Neuberg D; Shipp MA Clin Cancer Res; 2012 Mar; 18(6):1611-8. PubMed ID: 22271878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]